Busulfex

(busulfan)

ApprovedSmall molecule

Busulfan is used to treat certain blood cancers, particularly chronic myeloid leukemia, and is also used to prepare patients for bone marrow or stem cell transplants by destroying cancer cells and suppressing the immune system.[2] Busulfex is currently approved and in use across 81 indications[4].[1]

Busulfex is one of 873 small molecule programs targeting Graft Versus Host Disease. It is currently in Approved.

Indications

453

Total Trials

Active Trials

872

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Graft Versus Host DiseaseCompleted

Sickle Cell DiseaseCompleted

Acute Myeloid LeukemiaTerminated

MyelofibrosisCompleted

TransplantationCompleted

Wiskott-Aldrich SyndromeApproved

Niemann-Pick DiseaseApproved

Krabbe DiseaseApproved

HIV InfectionApproved

Non-Hodgkins LymphomaApproved

Graft Versus Host DiseasePhase 2

Completed

Sickle Cell DiseasePhase 2

Completed

Acute Myeloid LeukemiaPhase 3

Terminated

MyelofibrosisPhase 2

Completed

TransplantationPhase 2

Completed

Wiskott-Aldrich SyndromeApproved

Approved

Niemann-Pick DiseaseApproved

Approved

Krabbe DiseaseApproved

Approved

HIV InfectionApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Showing 10 of 81 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Busulfex

Akero Therapeutics

Approved

28 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—9

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Malignancy

NCT03674411

Q1 2027

Phase 1Active, not recruiting

Maintenance Therapy

NCT03613532

Q2 2027

Phase 2Active, not recruiting

Graft Versus Host Disease

NCT04859946

Q3 2027

Phase 2Not yet recruiting

Neuroblastoma

NCT05303727

Phase 3Not yet recruiting

Study completion

NCT06613035

Clinical

Trials by Indication[1]

Lymphoma17 trials

Autologous and Allogeneic Transplant for Relapsed Lymphoma

Completed·—·Phase 1/2·NCT00802113·30 enrolled

Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01983969·61 enrolled

Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas

Unknown status·AAzienda Ospedaliera San Giovanni Battista·Phase 2·NCT01786018·42 enrolled

Show 14 more trials

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

Completed·—·Phase 1·NCT01959477·33 enrolled

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Terminated·—·Phase 2·NCT01746173·5 enrolled

A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT02130869·8 enrolled

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)

Completed·SSoonchunhyang University Hospital·Phase 2·NCT03792815·51 enrolled

VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)

Unknown status·SSamsung Medical Center·Phase 2·NCT02544425·27 enrolled

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT02701673

Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00005824

Peripheral Stem Cell Transplantation Following Radiation Therapy in Treating Patients With Hodgkin's Disease or Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 2·NCT00004171

Chemotherapy and Radiation Therapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory T-cell Lymphoma, Hodgkin's Lymphoma, or Non-Hodgkin's Lymphoma

Completed·NNorthwestern University·Phase 1/2·NCT00004907

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00027937

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas

Recruiting·KKeimyung University Dongsan Medical Center·Phase 2·NCT02859402·34 enrolled

Tandem Auto-Allo Transplant for Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01181271·42 enrolled

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02961816

A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01625351·23 enrolled

Bone Marrow Transplantation13 trials

A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01349101·78 enrolled

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01135329·15 enrolled

Bone Marrow Transplantation, Hemoglobinopathies, SCALLOP

Terminated·TTami D. John·N/A·NCT00578344·8 enrolled

Show 10 more trials

HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide

Completed·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT02793544·80 enrolled

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00002547·280 enrolled

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002502

Total-Body Irradiation, Busulfan, and Interferon Alfa Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00003195

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00002798·880 enrolled

Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation

Terminated·UUniversity of Illinois at Chicago·Phase 2·NCT01749293·3 enrolled

Combination Chemotherapy Followed by Surgery and Peripheral Stem Cell or Bone Marrow Transplantation in Treating Infants With Newly Diagnosed Neuroblastoma

Completed·EEuropean Infant Neuroblastoma Study Group - 1999·Phase 2·NCT00025649

Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00705120·9 enrolled

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01338987·76 enrolled

Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)

Completed·MMedical College of Wisconsin·Phase 2·NCT02766465·138 enrolled

Stem Cell Transplant11 trials

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT00555048·1 enrolled

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·RRoswell Park Cancer Institute·N/A·NCT00536601·174 enrolled

Use of Busulfan as Conditioning Agent for a Second Stem Cell Transplant

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00092937·2 enrolled

Show 8 more trials

Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT02114502

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00357396·10 enrolled

Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders

Completed·UUniversity of California, San Francisco·Phase 2·NCT00301834·35 enrolled

Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML

Terminated·MMilton S. Hershey Medical Center·Phase 2·NCT04002115·2 enrolled

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Completed·UUniversity of Nebraska·Phase 2·NCT00611351·5 enrolled

Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders

Active, not recruiting·—·Phase 2·NCT00544115·260 enrolled

Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)

Terminated·—·Phase 1/2·NCT00579111·4 enrolled

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

Completed·NNorthside Hospital, Inc.·Phase 2·NCT00787761·24 enrolled

Myelodysplastic Syndrome11 trials

Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00475020·63 enrolled

CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Suspended·GGuenther Koehne·Phase 2·NCT05617625·50 enrolled

Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT01471444·256 enrolled

Show 8 more trials

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02250937·116 enrolled

Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01168219·68 enrolled

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00077116·31 enrolled

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·N/A·NCT00445744·52 enrolled

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00024050

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

Completed·—·Phase 1/2·NCT00003619

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00322101·25 enrolled

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Completed·—·Phase 2·NCT01177371·13 enrolled

Leukemia9 trials

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Completed·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT02799147·27 enrolled

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00357565·34 enrolled

Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03096782·6 enrolled

Show 6 more trials

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00049517·657 enrolled

CD34+ Transplants for Leukemia and Lymphoma

Not yet recruiting·GGuenther Koehne·Phase 2·NCT05565105·100 enrolled

Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00005940·18 enrolled

Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00055653

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002549·1,520 enrolled

Allogeneic Transplantation for Pediatric Leukemias With Unrelated Donors

Unknown status·—·Phase 1/2·NCT00679536·30 enrolled

72 more indications

Acute Myeloid Leukemia9 trials

Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

Withdrawn·GGuenther Koehne·Phase 1/2·NCT04982354

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT05449899·232 enrolled

Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia With Monosomy 7, -5/5q-, High FLT3-ITD AR, or Refractory or Relapsed Acute Myelogenous Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00553202·158 enrolled

Show 6 more trials

Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00630565·12 enrolled

Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00469014·72 enrolled

Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·WWashington University School of Medicine·Phase 1·NCT02057770·25 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02441803·11 enrolled

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT03247088·74 enrolled

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT03515707

Conditioning9 trials

BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03733327·20 enrolled

Decitabine + BUCY vs BUCY Conditioning Regimen for Myeloid Tumors Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04098653·196 enrolled

BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT

Completed·NNanfang Hospital, Southern Medical University·Phase 3·NCT02670252·550 enrolled

Show 6 more trials

G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04713956·242 enrolled

Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning

Not yet recruiting·IInstitut Paoli-Calmettes·Phase 2·NCT04451200·82 enrolled

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

Completed·Mmedac GmbH·Phase 3·NCT00822393·570 enrolled

Decitabine + BUCY vs BUCY Conditioning Regimen for TP53+ Myeloid Tumors Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT04123392·196 enrolled

Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03530085·60 enrolled

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

Completed·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT02744742·202 enrolled

Multiple Myeloma5 trials

Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma

Completed·—·Phase 2·NCT00004088·77 enrolled

A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT01413178·205 enrolled

High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT01534143·1 enrolled

Show 2 more trials

Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·—·Phase 2·NCT00941720·71 enrolled

Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01758328·29 enrolled

Neuroblastoma5 trials

Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma

Not yet recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT05303727·64 enrolled

Therapy for Children With Advanced Stage Neuroblastoma

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01857934·153 enrolled

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

Completed·CChildren's Oncology Group·Phase 1·NCT01175356·99 enrolled

Show 2 more trials

High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT04221035·800 enrolled

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Completed·CChildren's Oncology Group·Phase 1·NCT01798004·150 enrolled

Chronic Myelogenous Leukemia5 trials

Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT00446173

Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Completed·—·Phase 2·NCT00002592·40 enrolled

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

Completed·UUniversity of California, San Francisco·Phase 1/2·NCT00305708·40 enrolled

Show 2 more trials

Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia

Completed·NNorthwestern University·Phase 2·NCT00004181

Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00813124·24 enrolled

Acute Leukemia5 trials

Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00245115·7 enrolled

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00002831·24 enrolled

Decitabine+BUCY vs BUCY Conditioning Regimen for MLL+ Acute Leukemia Undergoing Allo-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03596892·122 enrolled

Show 2 more trials

Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT01498016·60 enrolled

Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02083250·70 enrolled

Allogeneic Stem Cell Transplantation4 trials

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

Completed·UUniversity of Chicago·Phase 1/2·NCT00943319·50 enrolled

Romidepsin Maintenance After Allogeneic Stem Cell Transplantation

Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT02512497·23 enrolled

Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation

Completed·MMassachusetts General Hospital·Phase 2·NCT01643668·34 enrolled

Show 1 more trial

Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study

Unknown status·AAlberta Health services·N/A·NCT00156858·200 enrolled

Hematopoietic Stem Cell Transplantation4 trials

Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in GRD

Unknown status·SSeoul National University Hospital·Phase 1/2·NCT02034630·5 enrolled

Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00668564·18 enrolled

Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Terminated·MMalika Kapadia·Phase 1·NCT05569512·1 enrolled

Show 1 more trial

Hematopoietic Stem Cell Transplantation With Targeted Busulfan and Fludarabine in Pediatric AML

Unknown status·SSeoul National University Hospital·Phase 2·NCT01274195·27 enrolled

Stem Cell Transplantation4 trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Unknown status·UUniversity of Leicester·Phase 3·NCT00020566·1,200 enrolled

Donor Stem Cell Transplantation for Congenital Immunodeficiencies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00426517·48 enrolled

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors

Terminated·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03615105·9 enrolled

Show 1 more trial

High-Dose Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Completed·—·Phase 2·NCT00003116·66 enrolled

Sickle Cell Disease3 trials

A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

Completed·SSangamo Therapeutics·Phase 1/2·NCT03653247·7 enrolled

Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00034528·2 enrolled

Stem Cell Transplant in Sickle Cell Disease and Thalassemia

Active, not recruiting·—·Phase 2·NCT00408447·53 enrolled

Chronic Granulomatous Disease3 trials

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT05463133·50 enrolled

Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT02282904·7 enrolled

Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)

Unknown status·SSeoul National University Hospital·Phase 1/2·NCT01338675·5 enrolled

Hematological Malignancies3 trials

Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies

Completed·—·N/A·NCT01247701·16 enrolled

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT05579769·3 enrolled

Stem Cell Transplantation for Hematological Malignancies

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00176839·11 enrolled

Graft Versus Host Disease3 trials

Itacitinib for the Prevention of Graft Versus Host Disease

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04859946·31 enrolled

Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03970096·120 enrolled

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00691015·48 enrolled

Hematologic Malignancies3 trials

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Withdrawn·BBaptist Health South Florida·Phase 2·NCT04282174

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Completed·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT01760655·62 enrolled

Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01471067·33 enrolled

Allogeneic Hematopoietic Stem Cell Transplantation3 trials

Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00990249·120 enrolled

Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·HHe Huang·Phase 1·NCT06809699·29 enrolled

Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation

Recruiting·HHe Huang·Phase 1·NCT06809712·29 enrolled

Myelofibrosis2 trials

PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis

Completed·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT02806375·20 enrolled

JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Active, not recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT02251821·61 enrolled

Efficacy and Safety2 trials

Efficacy and Safety of the Cryopreserved Formulation of OTL-101 in Subjects With ADA-SCID

Completed·UUniversity of California, Los Angeles·Phase 1/2·NCT02999984·10 enrolled

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

Not yet recruiting·RRuijin Hospital·Phase 3·NCT06297772·220 enrolled

Chronic Lymphocytic Leukemia2 trials

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Completed·GGerman CLL Study Group·Phase 1/2·NCT00281983·100 enrolled

Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00612716·6 enrolled

Refractory AML2 trials

T-Cell Depleted Double UCB for Refractory AML

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01464359·3 enrolled

CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML

Unknown status·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 3·NCT03384225·120 enrolled

Thalassemia2 trials

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Completed·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT04009525·823 enrolled

Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major

Unknown status·FFirst Affiliated Hospital of Guangxi Medical University·Phase 4·NCT03171831·30 enrolled

Ewing sarcoma2 trials

Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma

Withdrawn·—·N/A·NCT01795430

A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma

Withdrawn·UUniversity of Louisville·Phase 1·NCT01969942

Breast Cancer2 trials

Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients

Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT02670109·20 enrolled

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage II or Stage IIIA Breast Cancer

Completed·FFred Hutchinson Cancer Center·Phase 3·NCT00003972·280 enrolled

Severe Combined Immunodeficiency2 trials

Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Suspended·SSt. Jude Children's Research Hospital·Phase 1/2·NCT01512888·28 enrolled

Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency

Unknown status·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT03315078·13 enrolled

Transplantation2 trials

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Recruiting·NNantes University Hospital·Phase 2·NCT06252870·82 enrolled

Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01572662·201 enrolled

Bone Marrow Transplant2 trials

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00134017·142 enrolled

Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer

Active, not recruiting·—·Phase 2·NCT00534430·30 enrolled

Toxicity2 trials

Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma

Completed·UUniversity of Louisville·Phase 1·NCT02472392·10 enrolled

Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT05293509

Peripheral Blood Stem Cell Transplantation2 trials

Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation

Unknown status·—·Phase 4·NCT02784561·80 enrolled

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT03602898

Recessive Dystrophic Epidermolysis Bullosa1 trial

Allogeneic Stem Cell Transplantation (ALLOSCT) in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Terminated·—·Phase 1·NCT00881556·3 enrolled

Hematopoietic Cell Transplantation1 trial

Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation

Terminated·WWashington University School of Medicine·Phase 1·NCT02750254·5 enrolled

G-CSF1 trial

Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00822770·47 enrolled

Bone Marrow Failure Syndrome1 trial

Stem Cell Transplant for Bone Marrow Failure Syndromes

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2/3·NCT00176878·10 enrolled

Lenalidomide1 trial

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Completed·PPETHEMA Foundation·Phase 3·NCT01916252·460 enrolled

Non-malignant Disorders1 trial

Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders

Terminated·—·Phase 1/2·NCT00801931·1 enrolled

Efficacy1 trial

Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

Recruiting·NNantes University Hospital·Phase 2·NCT05917405·302 enrolled

Chemotherapy1 trial

Respiratory Side Effects of Busulfan High Dose Chemotherapy in a Pediatric Population

Unknown status·UUniversity Hospital, Strasbourg, France·Phase 2·NCT00328029·35 enrolled

Hematologic Cancer1 trial

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00304018·5 enrolled

PrEP1 trial

Targeted, Dose-Escalation Busulfan-Etoposide as Prep Regimen

Completed·UUniversity of California, San Francisco·Phase 1·NCT01048827·12 enrolled

Systemic Lupus Erythematosus1 trial

Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Terminated·NNew York Medical College·Phase 1·NCT00684255·1 enrolled

Myeloproliferative Neoplasms1 trial

Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT02410551·4 enrolled

Hematopoietic Cell Transplant1 trial

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00410982·145 enrolled

Treatment1 trial

ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

Completed·FFondazione Telethon·Phase 2·NCT00598481·12 enrolled

Phase II1 trial

Phase II Trial of Pentostatin and Targeted Busulfan

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00496340·42 enrolled

Allogeneic Hematopoietic Cell Transplant1 trial

Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation

Terminated·UUniversity of California, San Francisco·Phase 2·NCT01596699·16 enrolled

Haploidentical Stem Cell Transplantation1 trial

Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation (FluBuBe)

Completed·SSt. Petersburg State Pavlov Medical University·Phase 2·NCT04942730·50 enrolled

Hodgkin's Disease1 trial

High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01200329·81 enrolled

Pediatric Disorder1 trial

Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

Completed·—·N/A·NCT00950846·40 enrolled

TED1 trial

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03579875·48 enrolled

Intensity-modulated Radiation Therapy1 trial

Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer

Terminated·—·Phase 1/2·NCT00540995·25 enrolled

Metabolic Disease1 trial

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00003662·90 enrolled

Trial1 trial

Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00506857·82 enrolled

Glioma1 trial

Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas

Completed·—·N/A·NCT00253487

Acute Promyelocytic Leukemia1 trial

Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia

Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00002701·750 enrolled

Myelodysplastic Syndromes1 trial

Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Completed·TThe University of New South Wales·Phase 2/3·NCT00454480·2,000 enrolled

Safety and Efficacy1 trial

The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood Transplantation

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07441967·44 enrolled

Gene Therapy1 trial

Autologous Gene Therapy for Artemis-Deficient SCID

Recruiting·UUniversity of California, San Francisco·Phase 1/2·NCT03538899·24 enrolled

Recurrent or Metastatic1 trial

Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease

Completed·—·N/A·NCT00521430·30 enrolled

Aplastic Anemia1 trial

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

Unknown status·UUniversity of California, San Francisco·N/A·NCT00295997·35 enrolled

Maintenance Therapy1 trial

Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

Active, not recruiting·JJacqueline Garcia, MD·Phase 1·NCT03613532·102 enrolled

Tocilizumab1 trial

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Unknown status·YYi Luo·Phase 2·NCT04688021·46 enrolled

Prevention1 trial

Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03018223·32 enrolled

Juvenile Myelomonocytic Leukemia1 trial

Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT01824693·30 enrolled

Myeloproliferative Disorder1 trial

Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative Disorder

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00049634·30 enrolled

Stem Cells1 trial

Autologous CD34+ Hematopoietic Stem Cells Transduced ex Vivo With Elongation Factor 1 Alpha Shortened (EFS) Lentiviral Vector Encoding for the Human ADA Gene

Completed·UUniversity of California, Los Angeles·Phase 1/2·NCT01852071·46 enrolled

Malignancy1 trial

Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Active, not recruiting·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT03674411·22 enrolled

Myeloid Malignancies1 trial

VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

Not yet recruiting·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT07052422·160 enrolled

Patients With Solid Tumors1 trial

Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00003926·13 enrolled

Hematopoietic Cell Transplantation (HCT)1 trial

Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 4·NCT00361140·72 enrolled

T-cell non-Hodgkin lymphoma1 trial

Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT04220008

Acute Lymphoblastic Leukemia1 trial

Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia

Unknown status·IInstituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran·Phase 2·NCT03339700·15 enrolled

Central Nervous System (CNS) Tumors1 trial

Study of Busulfan for Refractory Central Nervous System (CNS) Tumors

Withdrawn·—·Phase 1·NCT00836628

APL1 trial

Alloreactive Haploidentical Natural Killer (NK) Cells With Busulfan and Fludarabine/ATG

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01390402·6 enrolled

Unspecified3 trials

Ruxolitinib in Combination With Autotransplant

Withdrawn·MMarina Kremyanskaya·N/A·NCT02469974

Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00800839·56 enrolled

Twice-per-weekSelinexor, 2 Days Melphalan

Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 3·NCT06613035·126 enrolled

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

MYLERAN

NDA NDA009386

Feb 4, 1999

BUSULFEX

NDA NDA020954

Sources

References

[1]
ClinicalTrials.gov — 453 trial records for busulfan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Busulfex drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — busulfan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for busulfan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020954). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Akero Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Akero Therapeutics